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Abstract 
Despite advances in multimodality treatment strategies for locally advanced rectal cancer and 
improvements in locoregional control, there is still a considerable variation in response to neoadjuvant 
chemoradiotherapy (CRT). Accurate prediction of response to neoadjuvant CRT would enable early 
stratification of management according to good responders and poor responders, in order to adapt 
treatment to improve therapeutic outcomes in rectal cancer. Clinical studies in diffusion-weighted 
imaging (DWI) and dynamic contrast-enhanced (DCE) MRI have shown promising results for the 
prediction of therapeutic response in rectal cancer. DWI allows for assessment of tumour cellularity. DCE-
MRI enables evaluation of factors of the tumour microvascular environment and changes in perfusion in 
response to treatment. Studies have demonstrated that predictors of good response to CRT include lower 
tumour pre-CRT apparent diffusion coefficient (ADC), greater percentage increase in ADC during and post 
CRT, and higher pre-CRT Ktrans. However, the mean ADC and Ktrans values do not adequately reflect 
tumour heterogeneity. Multiparametric MRI using quantitative DWI and DCE-MRI in combination, and a 
histogram analysis technique can assess tumour heterogeneity and its response to treatment. This 
strategy has the potential to improve the accuracy of therapeutic response prediction in rectal cancer and 
warrants further investigation. 
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ABSTRACT
Despite advances in multimodality treatment strategies for locally advanced rectal cancer and improvements in
locoregional control, there is still a considerable variation in response to neoadjuvant chemoradiotherapy (CRT).
Accurate prediction of response to neoadjuvant CRT would enable early stratification of management according to good
responders and poor responders, in order to adapt treatment to improve therapeutic outcomes in rectal cancer. Clinical
studies in diffusion-weighted imaging (DWI) and dynamic contrast-enhanced (DCE) MRI have shown promising results
for the prediction of therapeutic response in rectal cancer. DWI allows for assessment of tumour cellularity. DCE-MRI
enables evaluation of factors of the tumour microvascular environment and changes in perfusion in response to
treatment. Studies have demonstrated that predictors of good response to CRT include lower tumour pre-CRT apparent
diffusion coefficient (ADC), greater percentage increase in ADC during and post CRT, and higher pre-CRT Ktrans. However,
the mean ADC and Ktrans values do not adequately reflect tumour heterogeneity. Multiparametric MRI using quantitative
DWI and DCE-MRI in combination, and a histogram analysis technique can assess tumour heterogeneity and its response
to treatment. This strategy has the potential to improve the accuracy of therapeutic response prediction in rectal cancer
and warrants further investigation.
INTRODUCTION
Advances in multimodality treatment strategies over the
past decades have contributed to an improvement of out-
comes for patients with rectal cancer. The combination of
neoadjuvant chemoradiotherapy (CRT) and standardized
surgical technique (total mesorectal excision) has led to an
improvement in locoregional control, with local recurrence
rates dropping from 20–30% to 7–10% for patients with
locally advanced disease (T3–4 and/or N1–2).1,2 Neo-
adjuvant CRT followed by a 6- to 8-week break prior to
surgery has the advantage of tumour downstaging, with
a pathological complete response (pCR) achieved in
15–27% of patients.3 Despite these advances, tumour
responses to CRT still vary considerably, with 54–75% of
patients having tumour downstaging and the remainder
having no treatment response.4 The reason for this varia-
tion in treatment response is not well understood, and at
present, there is no accurate method of predicting treat-
ment response. Furthermore, distant metastases still
predominate with a 5-year cumulative incidence of 30% in
locally advanced (T3–4) resectable rectal cancer shown in
a pooled analysis of five Phase III randomized trials.2
More accurate imaging biomarkers for the prediction and
assessment of radiotherapy response would enable early
stratification of patients into different prognostic groups
and a personalized treatment approach. Identification of
patients with a clinical complete response prior to surgery
would enable optimization of the surgical approach with
“organ-preserving” procedures, which would result in
a reduction in surgical morbidity. It has been proposed that
patients with a clinical complete response may be able to
avoid surgery with a “wait and watch” policy;5 however,
accurate identification of patients with complete response
is crucial for this approach to minimize the risk of re-
currence. Early detection of poor responders to CRTwould
provide the opportunity for these patients to proceed di-
rectly to surgery thereby avoiding morbidity of CRT or for
intensified treatment regimens such as second-line chemother-
apy or higher radiation dose to maximize therapeutic response.
Functional imaging predictive biomarkers may be able to guide
individualization of patient treatment in order to maximize
therapeutic outcomes and minimize treatment toxicity. MRI has
the benefit of sampling the whole tumour and can be repeated
on multiple occasions unlike biopsy. Conventional pre-operative
staging investigations and histological examination of tissue bi-
opsies are not capable of predicting individual treatment re-
sponse. Although MRI using standard morphological sequences
(T2 weighted) is important for staging and treatment planning,
6
it is inadequate for prediction and assessment of individual re-
sponse to CRT. Current predictive models require pathological
staging, making them unsuitable for use as a pre-treatment
decision support tool.2,7 Recent research efforts have focused on
using physiological information from functional MRI techni-
ques to more accurately predict treatment response; however,
the clinical role of functional MRI is yet to be defined.
This expert review assesses the current status on functional MRI,
from the clinical utility in prediction of CRT response through
to the ex vivo analysis and characterization of rectal cancer. This
review summarizes the existing literature on clinical potential of
diffusion-weighted imaging (DWI) and dynamic contrast-
enhanced (DCE) MRI in prediction of CRT response, progno-
sis and biological characterization of tumour and the ex vivo
high-field MR spectroscopy (MRS) in the metabolic character-
ization of rectal cancer.
Potential benefits of MRI/MR
spectroscopy biomarkers
The development and discovery of MRI/MRS biomarkers can
improve the clinical management of rectal cancer. The foresee-
able benefits are:
(i) MRI/MRS provides a non-invasive technique that can assess
the entire tumour region, thereby yielding information
about tumour heterogeneity and avoiding sampling error
associated with conventional biopsy techniques.
(ii) New MRI/MRS biomarkers will better reflect patient
prognosis and response to different treatment options, thus
facilitating individually tailored medical management and
monitoring of outcomes. This can enable early stratification
of patients into high-risk groups, for de-escalation of
treatment (e.g. exclusion of surgery or sphincter-sparing
techniques in patients with pCR) or low-risk groups for
intensification of treatment.
FUNCTIONAL MRI FOR CLINICAL THERAPEUTIC
RESPONSE PREDICTION AND ASSESSMENT IN
RECTAL CANCER
The development of functional MRI sequences has enabled the
assessment of different biological tumour characteristics and is
an important advance in imaging evaluation in oncology.
Standard morphological MRI (T2 weighted) has been shown to
have significant correlation with survival outcomes in the MRI
and Rectal Cancer European Equivalence (MERCURY) study,8
a large prospective trial assessing the prognostic significance of
post-CRT MRI assessment of tumour regression grade (TRG).
However, volumetric measurements based on standard mor-
phological MRI lack sufficient accuracy for the differentiation of
treatment responders from non-responders because of their
inability to detect small residual tumour deposits within areas of
radiation-induced fibrosis. Functional MRI biomarkers have
been documented to have greater potential compared with
standard T2 weighted sequences in the assessment of therapeutic
response in patients with locally advanced rectal cancer un-
dergoing neoadjuvant CRT.9 The clinical utility of these func-
tional MRI biomarkers in rectal cancer is still yet to be defined.
DIFFUSION-WEIGHTED MRI
DWI is a functional MRI technique which is sensitive to the
movement of water molecules through the body. The apparent
diffusion coefficient (ADC), a quantitative parameter used for
assessment of water diffusion through tissue, shows an inverse
relationship with tissue cellularity.10 Viable tumour cells restrict
the mobility of water, whereas necrotic tumour cells allow in-
creased diffusion of water molecules. Increasing tumour cellu-
larity and architectural distortion of the extracellular space will
contribute to decreased ADC values. The ADC values have been
shown to correlate with tumour cellularity and grade.11 The
ADC has been shown to differentiate post-treatment persistent
tumour from inflammation and necrosis, making it a useful tool
to monitor effects of radiotherapy. Radiotherapy-related cellular
damage leading to necrosis can occur within days of initiating
therapy. The ability to detect changes in tumour microstructure
allows DWI to be used for early treatment predictions.12,13
Prediction and assessment of primary
tumour response
Prospective studies have evaluated the use of DWI in the pre-
diction and assessment of primary response to CRT in rectal
cancer. The majority of these studies demonstrated ADC to be
useful for distinguishing good responders from poor responders,
with the standard histological reference based on TRG. The key
findings in prospective studies of DWI for assessment of CRT
response are shown in Table 1. In general, studies demonstrated
predictors for good responders have a lower pre-CRTADC value
and a greater percentage increase in ADC during and post CRT.
Performance of pre-treatment ADC values for prediction of
good responders is variable between small prospective studies,
with sensitivities, specificities, positive-predictive values (PPVs)
and negative-predictive values (NPVs) ranging from 62% to
100%, 86–91%, 67–79%, and 62–100%, respectively.13–15 One
study16 demonstrated that pre-treatment ADC was not a signif-
icant predictor of treatment response. The performance of post-
treatment percentage increase (41–59%) in ADC for detection of
good responders produced PPV and NPV ranging from 82 to
91% and from 43 to 94%, respectively.15,16 In another study,17
a post-treatment mean ADC cut-off of 1.0453 1023mm2 s21
was associated with a sensitivity and specificity of 75% and
100%, respectively. These DWI studies used echo planar imaging
(EPI) and multiple b-values (range between 0 and 1000).
However, there were a number of differences that may account
for the variations in results observed between studies. The
standardization of MRI protocols is important to compare
quantitative studies; the differences in the number of b-values
BJR Pham et al
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and b-values used in the protocols could result in differences in
the ADC maps produced, making it difficult to compare studies.
The imaging analyses and quantification methods varied be-
tween studies; Lambrecht et al14 defined the region of interest
(ROI) on b5 0 and b5 1000 images; Barbaro et al13 defined the
ROI on ADC maps, matching with corresponding T2 weighted
images, and Intven et al15 used in-house software for their
analysis.
A meta-analysis by van de Paardt et al,9 which included six DWI
studies, has compared the performance of DWI with standard
morphological MRI (T2 weighted) in assessment of treatment
response post CRT. DWI showed significantly better results for
tumour re-staging compared with standard morphological
sequences. They found that DWI had a mean sensitivity of
83.6% (95% CI 61.7–94.2%) and specificity of 84.8% (95% CI
74.2–91.5%). Studies with experienced observers showed sig-
nificantly better results, with higher sensitivity for re-staging,
than studies with less experienced observers.
There are limited prospective studies examining the value of
DWI during CRT.13,14 These studies showed that the percentage
increase in ADC during Week 2 of CRT was predictive of re-
sponse. This is potentially useful in identifying poor responders
early during treatment, to provide an opportunity to change the
treatment approach and to prevent them from proceeding with
likely futile treatment. Further investigation of DWI performed
during CRT is warranted.
ADC cut-off values for response in studies were chosen on an ad
hoc basis and still require prospective validation in larger patient
populations. Furthermore, there was a wide variation in per-
formance of ADC values demonstrated between studies. Al-
though promising, DWI currently lacks sufficient accuracy for
clinical use to stratify patients into adaptive management
pathways. The above rectal cancer diffusion studies used con-
ventional single-shot EPI. More recent improvements in these
sequences, such as readout segmented diffusion technique
(RESOLVE), have improved detail and decreased image distor-
tion compared with standard EPI diffusion. The benefit of RE-
SOLVE for therapeutic response prediction warrants further
investigation in rectal cancer.
Assessment of nodal response
The van der Paardt meta-analysis found that MRI, including
standard morphological sequences and DWI studies, cannot
discriminate nodal response to treatment.9 However, it was not
specified how many DWI studies formed part of this analysis.
One DWI prospective study of 30 patients by Lambregts et al18
specifically assessed the performance of ADC for nodal staging
after completion of CRT. They found that DWI on its own was
not reliable and did not improve accuracy of nodal staging when
performed in addition to T2 weighted sequences.
Identification of pathological complete response
Between 15% and 27% of patients will have a pCR following
CRT. This represents an important subgroup of patients in
whom surgery could be avoided with a “wait and watch” policy,
or morbidity of surgery can be reduced with sphincter-sparing
surgical techniques. Accurate identification of these patients is of
great importance prior to considering more conservative man-
agement options. There are only 5 small prospective
studies14,15,19–21 assessing the role of DWI in detection of pCR;
the remainder of studies are retrospective series.22–24 The key
findings from these studies are summarized in Table 2. The
majority of these studies have shown that it is possible to identify
patients with pCR through early prediction pre CRT or assess-
ment post CRT.
Multiple studies14,15,19 have found that a lower pre-treatment
mean ADC had value in prediction of patients who went on to
have a pCR, although this was not significant in Genovesi et al.19
Lambrecht et al14 studied DWI performed at multiple time
points for the assessment of pCR in a prospective study of
20 patients. They found that pre-CRT ADC had a sensitivity of
100% and specificity of 86% in prediction of pCR.
In the post-CRT assessment of CRT response, Intven et al15 and
Genovesi et al19 found that change in the ADC post CRT could
identify pCR, with diagnostic accuracy of 98% and 91% in the
studies, respectively. Lambrecht et al14 found that ΔADC post CRT
was also useful in the detection of pCR. These results have not
always been replicated, with some investigators finding that DWI
does not unequivocally determine pCR.20 A large retrospective
multicentre study22 of 120 patients found that the addition of DWI
to standard morphological sequences improved the selection of
pCR after CRT. DWI analysis by observers in this study was
qualitative and therefore did not use the ADC values. With T2
weighted MRI alone, the sensitivity for identification of pCR was
poor ranging from 0% to 40%. The addition of DWI improved the
sensitivity to 52–65% and had a specificity of 89–98%.
It is difficult to accurately identify pCR on DWI alone, and this
modality may need to be combined with another modality. It is
expected that in patients with no residual tumour, diffusion will
be freer and restriction will not remain on the post-CRT scan.
However, a study25 assessing the post-CRT DWI of patients with
confirmed pCR has shown that this is not always the case. Jang
et al25 retrospectively reviewed post-CRT DWI of 43 patients who
had undergone neoadjuvant CRT, subsequent surgery and ach-
ieved pCR. They reported diffusion restriction remained in 42%
of patients with pCR. Radiation proctitis and fibrosis, demon-
strated on histopathology, were significant independent predictors
of diffusion restriction in patients achieving pCR after CRT. This
study has shown that even in the absence of residual tumour,
restricted diffusion can still occur as a result of radiation-induced
fibrosis, making it difficult to accurately identify all patients with
pCR on DWI alone. A study by Maas et al21 on 50 patients found
that post CRT, qualitative T2 weighted imaging and DWI had low
sensitivity of 35% and specificity of 94% for the prediction of
pCR. However, combining MRI with clinical assessment, con-
sisting of digital rectal examination and endoscopy, improved the
prediction of pCR with a post-test probability for predicting pCR
of 98%. This study demonstrated that DWI alone is poor at
detecting pCR and needs to be combined with another modality.
Joye et al26 performed a systematic review on the role of DWI in
the prediction of pCR in response to CRT. Pooled data from
BJR Pham et al
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9 studies with a combined total of 226 patients demonstrated
that the ADC pre CRT was unable to predict for pCR with
a sensitivity of 69%, specificity of 68%, PPV of 35% and NPVof
90%. Pooled data from 10 studies with a combined total of
315 patients found that the ADC post CRT had sensitivity of
78%, specificity of 72%, PPV of 47% and NPV of 91% for
detection of pCR. However, the lack of standardization of MRI
protocols and image quantification methods between different
centres would limit the potential of pooled analysis.
DYNAMIC CONTRAST-ENHANCED MRI
DCE-MRI provides functional information on tumour micro-
vessel perfusion, permeability and extracellular-extravascular space
composition by assessing the changes in signal intensity over time
following intravenous injection of a paramagnetic contrast agent.
ROIs may be interrogated to produce enhancement–time curves
with malignant tumours, due to their abnormal microvasculature,
demonstrating a rapid washin and washout of contrast and
a greater increase in signal intensity than in normal tissues.10,27
DCE-MRI may be able to assess characteristics of the tumour
vascular microenvironment, such as hypoxia and microvascular
density that influence radiotherapy response, and also vascular
changes induced by radiotherapy. DCE-MRI can potentially assess
tumour downstaging, therefore distinguishing good responders
from poor responders to treatment. The perfusion character-
istics on DCE-MRI can be analysed either in a quantitative28 or
qualitative technique, hence the published studies are difficult
to compare. Quantitative analysis involves modelling the
Table 2. Diffusion-weighted imaging (DWI) MRI studies—identification of pathological complete response (pCR)—ypT0 vs non-pCR
after chemoradiotherapy











During DADC (72 vs 16) and












DADC (%) better than T2W
Dvolume (%) in detection
of pCR
p5 0.022
Engin et al (2012)20 30 Pre, post
DWI qualitative—SI,
ADC (mean)
Post-DSI and Post-DADC NS
Maas et al (2015)21 50 1.5 T Post T2W and DWI—qualitative
Detection of pCR: sensitivity
35%, specificity 94%
Combining T2W, DWI and
clinical assessment improves






1.5 T Post Qualitative
Detection of pCR:
DWI vs T2W alone (sensitivity
52–64% vs 0–40%, specificity
the same 89–98%)
Sassen et al (2013)23 70
1.5 T
Pre, post
















ADC and DADC (%) NS
Post-ADC volume (0.03 pCR vs
1.5 non-pCR) and Dvolume


















Post-ADC (1.33 vs 1.13) 0.002
ADC, apparent diffusion coefficient; NS, not significant; SI, signal intensity; T2W, T2 weighted; VDWI, DWI volume.
Review article: Functional MRI for rectal cancer treatment response prediction BJR
5 of 14 birpublications.org/bjr Br J Radiol;90:20151078
pharmacokinetics of an intravenously administered contrast
agent and requires correction for T1 pre-contrast. Investigation
into DCE-MRI is sparse, and its clinical role in response pre-
diction and assessment and optimal evaluation technique is yet
to be established.
Prediction of therapeutic response
Several quantitative studies assessing tumour response with
DCE-MRI have shown that higher contrast exchange rates pre
CRT, which indicates higher tumour permeability, are associated
with better therapeutic response to CRT. Key findings from
studies evaluating the role of DCE-MRI in therapeutic response
assessment are shown in Table 3. In a prospective study of
95 patients, a higher pre-treatment K21 (contrast medium ex-
change in the Brix pharmacokinetic model) was significantly
associated with good treatment response, defined as post-
treatment pT0-2N0 Union for International Cancer Control
(UICC) stage.29 On multivariate analysis, a higher 75th per-
centile K21 was associated with a higher tumour response rate,
whereas the DCE-MRI quantitative parameters—amplitude and
time to peak—were not associated with tumour response. In
addition, mucinous tumour morphology was significantly as-
sociated with poorer response to treatment. Other quantitative
studies demonstrated higher pre-CRT Ktrans (contrast medium
exchange in the Tofts pharmacokinetic model) was predictive
of tumour response.30,31 Intven et al30 found in a study of
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51 patients that pre-CRT Ktrans (50th percentile) was significantly
higher in patients with good therapeutic response as defined by
Mandard TRG 1–2. Similarly, George et al31 showed that responsive
tumours had higher pre-treatment Ktrans than non-responsive
tumours. This result was also demonstrated in Lim et al,32 although
not significant. Results on the predictive value of post-CRT DCE-
MRI were less clear, with Intven et al30 and George et al31 dem-
onstrating a correlation between a reduction in post-CRT Ktrans and
good response, and Lim et al showing no correlation.
The role of DCE-MRI derived quantitative parameters in the
prediction of therapeutic response to CRT was explored in
a study of 30 patients by Martens et al.33 Six semi-quantitative
parameters from pre-CRT and post-CRT DCE-MRI were in-
vestigated: (i) initial slope, (ii) initial peak, (iii) areas under the
first 60, 90 and 120 s of the enhancement curve and (iv) late
slope. Only pre-CRT late slope was able to discriminate between
good and poor responders to treatment (20.0531023 vs
0.6231023, p, 0.001).
There are a variety of quantitative measurements that can be
obtained from DCE-MRI that can be obtained through a simple
approach or through pharmacokinetic quantification models. A
simple analysis uses a curve descriptor to characterize the signal
intensity curve.34 Examples of this include area under curve and
initial peak used in the study by Martens et al.33 Pharmacoki-
netic modelling includes the Brix and the Tofts models. K21 is
derived from the original Brix model,35 a simple linear two-
compartment model that does not require T1 mapping or ar-
terial input function measurements. K21 can measure the rate
constant between the extravascular extracellular space and
plasma, but a major disadvantage is that it does not measure
perfusion. There has been a shift towards using the Tofts model,
which provides values that more closely represent pathophysi-
ological processes, such as perfusion. Kep in the Tofts model can
measure rate constant between extravascular extracellular space
and plasma, a value similar to K21 in the Brix model. K
trans in the
Tofts model is the influx volume transfer constant from the
plasma into the extravascular extracellular space. The calculation
of Ktrans requires pre-contrast T1 measurement and takes into
account the arterial input factor, hence this parameter more
closely represents physiological perfusion.28,36 At present, Ktrans
appears to be the most promising parameter for the prediction
of treatment response in rectal cancer.
Most DCE-MRI studies assess therapeutic response in the primary
tumour. There is a lack of studies on the potential of DCE-MRI
in nodal therapeutic response assessment. The ability of DCE-MRI
to assess nodal response to treatment has been explored only in a
study of 55 patients who underwent DCE-MRI following
completion of CRT. In this study, Alberda et al37 assessed the
accuracy of qualitative DCE-MRI methods, with histopatho-
logical assessment of nodes being the standard reference. They
found that early incomplete arterial phase enhancement on
DCE-MRI was a significant indicator of malignant nodes.
Prognostic value
The prognostic value of DCE-MRI in rectal cancer has been
investigated by DeVries et al.38 In a prospective study of
83 patients with T3 rectal cancer undergoing neo-adjuvant CRT,
DeVries et al investigated the value of the pre-CRT perfusion
index, a microcirculatory parameter which integrates in-
formation on flow and permeability, in the prediction of ther-
apeutic disease-free survival and overall survival. A lower pre-
treatment mean perfusion index was found to be significantly
predictive of therapy response (defined as ypT0-2). After a mean
follow-up of 716 29 months, the perfusion index significantly
predicted disease-free survival (hazard ratio 1.84, p, 0.001) and
overall survival (hazard ratio 1.42, p5 0.04), with patients with
lower perfusion index having worse survival.
Biological correlation
DCE-MRI allows functional characterization of biological changes
in the tumour microvasculature.27 The findings from studies
correlating DCE-MRI with tumour biological characteristics are
summarized in Table 4. Clinical DCE-MRI studies in rectal cancer
have shown correlation of DCE-MRI parameters with variables of
tumour angiogenesis relevant to radiation response.29,31,39–41 A
prospective study39 of 17 patients showed that DCE-MRI can be
used to assess radiation-induced changes in tumour vasculature.
Radiotherapy inhibits tumour angiogenesis, which correlated with
a significantly lower microvessel density (MVD) compared with
non-irradiated tumours. Similarly, Kps, the endothelial transfer
coefficient, was found to be 77% (p5 0.03) lower in the
radiotherapy-treated group. Hong et al42 also showed that DCE-
MRI could be used to assess tumour angiogenesis. The semi-
quantitative parameter of Emax (maximal enhancement) had
a significant correlation with microvessel count.
Yeo et al40 performed a retrospective analysis of pre-operative
DCE-MRI in 31 patients undergoing surgery alone, and pre-CRT
and post-CRT DCE-MRI in 15 patients undergoing CRT.
Quantitative parameters including Ktrans, Ke, K
trans, Kep, extravas-
cular extracellular fractional volume (Ve), and initial area under the
concentration curve in 60 seconds (iAUC) were correlated with
histological markers of tumour aggressiveness [expression of epi-
dermal growth factor receptor (EGFR) and KRAS gene mutations],
tumour angiogenesis (MVD) and vascular endothelial growth
factor (VEGF). They found that a higher mean Ktrans and Kep
correlated with increased tumour aggressiveness, as indicated by
the presence of an EGFR mutation. Furthermore, the mean Kep
from the high Ktrans area had a significant positive correlation with
MVD (higher mean Kep, correlated with greater MVD). However,
there was no correlation between DCE-MRI and VEGF in this
study. In another study by George et al,31 there was a correlation in
Ktrans and VEGF before treatment; however, this correlation was no
longer present after the commencement of treatment.
MR SPECTROSCOPY: METABOLIC IMAGING
MRS is an important tool for studying cancer metabolism. It can
improve the understanding of the altered metabolic pathways in
cancer and identify new metabolic biomarkers for treatment re-
sponse prediction, prognosis and novel therapeutic targets. The
discovery of an activated choline metabolic pathway in cancer was
mostly due to MRS studies of tumours in the 1980s.43 This
pathway is characterized by increased choline-containing com-
pounds, such as phosphocholine, glycerophosphocholine and
total choline-containing compounds, which are detectable by
Review article: Functional MRI for rectal cancer treatment response prediction BJR
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non-invasive MRS. The increased choline compounds are caused
by malignant transformation and the hypoxic and acidic micro-
environment of tumour. Enzymes of choline metabolism, such as
choline kinase, may provide novel therapeutic targets.
MRS is a unique technique that can be applied with high
resolution, as an initial ex vivo metabolic screening tool on
tissue samples, and then translated into lower resolution in vivo
MRS protocols for clinical use. MRS can identify the “spectral
fingerprint” of cancer subtypes due to its ability to detect
multiple tissue-specific metabolites in a single experiment. It is
a quantitative technique with the intensities of MRS signal
being directly related to metabolite concentration.44 Analysis of
intact tissue using standard MRS techniques result in spectra
with lower resolution than normal liquid-state spectra. The
resolution of tissue spectra can be improved by applying high-
resolution magic angle spinning, a specialized MRS technique
that detects high-resolution spectra by spinning solid tissue
samples at the angle of 54.7°. High-resolution magic angle
spinning profiling of intact tissue produces spectra that ap-
proach the resolution of solution-state samples.45 An advan-
tage of this technique is that tissue sample preparation results
in minimal tissue destruction, allowing for correlation with
histological and molecular analysis of the same tissue sample
post MR analysis.
Ex vivo MR spectroscopy: prediction of disease
behaviour and survival
A small number of studies have highlighted the potential of
metabolic profile derived from ex vivo MRS tissue analysis in
predicting disease behaviour46 and survival outcomes.47,48 The
key findings are summarized in Table 5. Pacholczyki-Sienicka
et al47 analysed frozen tissue samples from surgical specimens
of 52 patients with colorectal cancer who underwent surgery
using 700.33-MHz (16.4-T) proton (1H) MRS. Survival time
was defined as the interval from surgery until death or the end
of a 5.5-year observation period. They found that long-term
survival in patients was characterized by lower levels of choline
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compounds (choline, phosphocholine, glycerylphosphor-
ylcholine), glycine, lactate and myo-inositol compared with
non-survivors. Choline compounds have been found to be
associated with malignant transformation, therefore this find-
ing of a lower level of choline compounds in long-term
survivors is biologically plausible. In addition, they found that
an increase in taurine/glycine (sensitivity 64% and specificity
96%) and taurine/myo-inositol (sensitivity 65% and specificity
100%) ratios were significantly higher in survivors than in
non-survivors.
Jimenez et al48 also found that metabolic profiling of colorectal
cancer samples was predictive of 5-year survival. However, this
study found that metabolic changes predictive of survival oc-
curred in tumour-adjacent macroscopically normal colon,
5–10 cm from the tumour. The authors suggest this represents
a “field cancerization” effect, whereby the tumour affects the
metabolism of its surroundings. However, the metabolic profile
within the tumour specimens was not predictive of survival.
MRS metabolic profiling can potentially predict patients at
risk of tumour recurrence.46 Minicozzi et al proposed
a marker of malignancy (MRS-tm) based on the metabolic
findings in a study by Chan et al.49 MRS-tm was defined as
the ratio between the sum of the amplitudes of increasing
components with peak between 3.0 and 3.8 ppm (including
choline-containing compounds, taurine, scyllo-inositol and
glycine) to the amplitude of the lipid methylene at 1.3 ppm.
4.7-T 1H-MRS was performed on 29 surgical specimens. The
MRS-tm was calculated for each specimen for tumour com-
pared with healthy mucosa. The results demonstrated
that MRS-tm was higher in tumour than normal mucosa. At
5-year follow-up, they reported statistical significance for
tumour MRS-tm when patients were discriminated according
to disease progression (either local recurrence or distant
metastases). 5 of 6 patients with disease progression had
a tumour MRS-tm ,0.1, whereas 16 of 18 disease-free
patients had MRS-tm .0.1 (p5 0.04).
Clinical MR spectroscopy
One published study50 assessed the use of MRS in vivo in
patients with rectal cancer. Kim et al50 performed 1H-MRS at 3 T
with a 6-channel phased-array pelvic coil in 34 patients with
rectal cancer at diagnosis and after neoadjuvant CRT. They
found that the choline peak at 3.2 ppm was characteristic of
rectal cancer at diagnosis. Following CRT, the choline peak
disappeared and only the lipid peaks remained in 33 patients
post CRT. The study identified three spectral types and found
that 67% of patients with a post-CRT spectral type containing
lipid peaks at 1.3 and 0.9 ppm at both long and short echo times
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had histological residual tumour. The lipid in normal controls
was present at short echo time only, and the authors hypothe-
sized that the nature of the lipid was different in patients with
residual tumour compared with normal controls. This study
showed that MRS metabolic profiling in vivo may have the
potential to identify tumour at diagnosis and changes in the
metabolic profile post CRT may be used to assess treatment
response.
Translation of ex vivo to clinical MR spectroscopy
Choline is currently the most investigated metabolite in ex vivo
and clinical studies. Ex vivo studies have shown higher levels of
choline-containing compounds in colorectal tumour.46,49 Ex
vivo studies have demonstrated lower levels of choline-
containing compounds and glycine, and higher taurine ratios
in surgical specimens were associated with longer survival in
patients with colorectal cancer.47 The clinical MRS study found
choline to be a potential biomarker of treatment response, with
results showing a choline peak characteristic of rectal cancer at
diagnosis and disappearance of this peak post CRT.50 However,
further clinical studies are required to translate high field ex vivo
findings to clinical protocols and to assess whether choline
would be a useful biomarker in the assessment of response to
CRT (good vs poor response) and prediction of survival. Clinical
studies are also required to assess whether taurine and glycine
are useful clinical biomarkers in rectal cancer treatment re-
sponse. Furthermore, there are some challenges in the trans-
lation of ex vivo MRS findings to MRI protocols to current
clinical strengths (1.5–3 T) that need to be overcome. Localiza-
tion of metabolite, weak metabolite signal relative to the larger
water signal, in vivo can present challenges to clinical
translation.44
FUTURE DIRECTIONS: MULTIPARAMETRIC MRI
AND HISTOGRAM ANALYSIS
Although the evidence for DWI and DCE-MRI is promising,
results from either of these techniques alone currently lack
sufficient accuracy and standardization to be routinely used to
alter clinical patient management. There is a wide variation
reported in the performance of functional MRI in response
prediction. Parameter thresholds obtained from studies require
prospective validation of post hoc values in larger prospective
studies. Most published studies have measured single parameter
values from either diffusion or perfusion MRI. Single-parameter
measurements, such as mean ADC or Ktrans of pixels in the ROI,
do not reflect tumour heterogeneity.
Figure 1. Diffusion-weighted imaging (DWI) MRI histogram analysis—apparent diffusion coefficient (ADC) colour-coded maps and
histograms of a patient with good response following neoadjuvant chemoradiotherapy for rectal cancer. Example of ADC histogram
analysis using Siemens OncoTreat (WIP), Erlangen, Germany. This patient had histological American Joint Committee on Cancer
(7th edition) tumour regression grade 1 (moderate response, single cells or small groups of cancer cells). A voxel-by-voxel technique
was used to assess changes in the entire region of interest. (a, c, e) Representative axial colour-coded ADC maps for MRI pre-
chemoradiotherapy (CRT), Week 3 of CRT and post CRT, respectively. (b, d, f) Colour-coded histograms for every voxel within the
segmented region of interest for DWI-MRI pre-CRT, Week 3 of CRT and post-CRT, respectively. Colour code: blue voxels, ADC
values ,10003 1026; green voxels, ADC values 10002 15003 1026; red voxels, ADC values .15003 1026. The histograms
demonstrate an increase in the absolute ADC values of voxels over the time points.
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Multiparametric MRI combining multiple functional parameters
can provide a more complete physiological assessment of
tumour, which may improve accuracy in response prediction.
A combined analysis of DWI and DCE-MRI would provide
complementary information on tumour microarchitecture and
cellularity (DWI) and angiogenesis and perfusion (DCE-MRI).51
For example, in the case of pCR, the presence of radiation-
induced fibrosis may cause restricted diffusion resulting in low
ADC and inability to detect pCR on DWI. The addition of DCE-
MRI would allow assessment of perfusion within this region; the
absence of perfusion or low Ktrans would indicate the absence of
residual tumour, which may improve the detection of pCR.
Multiparametric functional MRI for response prediction is an
emerging area, and currently, there are limited studies assessing
the role of DWI and DCE-MRI in combination in rectal cancer
CRT response prediction. Intven et al demonstrated that good
responders to CRT had a larger decrease in median Ktrans and
larger increase in median ADC post CRT than non-responders.
However, the addition of DCE-MRI did not improve the de-
tection of good responders compared with the use of DWI
alone.52 A histogram analysis that incorporates a voxel-by-voxel
technique to calculate MRI functional parameters for every voxel
within the ROI would provide a more accurate representation of
intratumour heterogeneity.53 A histogram technique can be
sensitive to a shift in distribution of ADC or Ktrans values of all
voxels within the entire tumour region over the time points,
thereby providing information on any heterogeneity in tumour
response to treatment. Other information such as mean, mode,
skewness and percentile distributions can also be extracted.
Overall trends from histogram studies have shown that follow-
ing treatment, DWI (ADC) histograms demonstrate a shift to
the right with decreased skewness and kurtosis, and DCE-MRI
histograms shift to the left with narrower and increased peak
height.53 A new analysis software is being investigated that
allows this analysis to be conducted for multiple parameters,
allowing for multiparametric histogram analysis. An example of
voxel-by-voxel histogram analysis is shown in Figures 1 and 2.
Furthermore, semi-automated segmentation tools can also re-
duce interobserver variability in defining a three-dimensional
ROI and lead to more reproducible results.
The fundamental aspect to multiparametric imaging is
achieving a standardized imaging protocol that provides con-
sistent and reliable data sets for quantification. For voxel-wise
analysis of multiple functional MRI sequences, selection of
imaging parameters that minimize distortion is essential to
ensure geometrically accurate data. For DWI, RESOLVE is one
method to minimize distortion.54 For DCE-MRI, short tem-
poral resolution of between 5 and 10 s would enable adequate
sampling of the rapid “washin” of contrast into tumour, and
Figure 2. Dynamic contrast-enhanced (DCE) MRI histogram analysis—Ktrans colour-coded maps and histogram of the same patient
with good response following neoadjuvant chemoradiotherapy for rectal cancer. Example of Ktrans histogram analysis using Siemens
OncoTreat (WIP) for the same patient as in Figure 1. A voxel-by-voxel technique was used. (a, c, e) Representative axial colour-
coded Ktrans maps for MRI pre-chemoradiotherapy (CRT), Week 3 of CRT and post CRT, respectively. (b, d, f) Colour-coded
histograms for every voxel within the segmented region of interest for DCE-MRI pre CRT, Week 3 of CRT and post CRT,
respectively. Colour code: blue voxels, Ktrans values ,1003 1023; green voxels, Ktrans values 1002 5003 1023; red voxels, Ktrans
values .5003 1023. The histograms demonstrate a marked reduction in the absolute Ktrans values of voxels over the time points.
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acquisition of pre-contrast T1 flip angle scans would enable
calculation of native T1, allowing for more accurate assessment
of perfusion using the Tofts two-compartment model. Al-
though multiple parameters can be obtained from DWI and
DCE-MRI, at present, ADC and Ktrans appear to be the most
promising parameters for clinical prediction of radiotherapy
response in rectal cancer. Standardization of imaging protocols
and analysis methods is essential in order to establish optimal
thresholds of ADC and Ktrans and to permit the clinical role of
multiparametric MRI for treatment prediction to be properly
evaluated.
CONCLUSION
Functional MRI is emerging as an important and promising tool
for assessment of physiological characteristics of the tumour
microenvironment. MRI has the benefit of sampling the whole
tumour and can be repeated on multiple occasions unlike
biopsies.
DWI has been shown to be superior to morphological MRI in
the assessment of therapeutic response of the primary tumour
in rectal cancer. In general, studies have demonstrated that
lower primary tumour pre-CRT ADC value and greater per-
centage increase in ADC during CRT are predictors for good
response. There is limited prospective data on the use of
DWI for identification of patients with pCR, an important
subgroup of patients in whom early MRI detection of CR
would enable optimization of the surgical approach and
reduction in surgical related sphincter morbidity. DCE studies
have demonstrated that high tumour Ktrans pre-CRT is a
predictor for response. The role of MRS in the clinical
management of rectal cancer remains yet to be defined.
Although published ex vivo studies have identified colorectal
cancer-specific metabolic profiles that can aid with prediction
of disease behaviour, there is only one clinical rectal MRS
study which identified choline as a potential biomarker of
CRT response.
Multiparametric MRI assessing diffusion and perfusion in
combination using a histogram analysis technique can assess
tumour heterogeneity and its response to treatment. This
strategy has the potential to improve the accuracy of therapeutic
response prediction and facilitate individualized management
for patients with rectal cancer.
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